BLOOMFIELD, Conn., Dec. 19, 2023 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) announced today that David Cordani, chairman and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 in San Francisco, CA.
The Cigna Group's presentation is expected to begin at approximately 10:30 a.m. ET. A live webcast of the presentation will be available at https://investors.thecignagroup.com/events-and-presentations/default.aspx in the Investor Relations section of The Cigna Group's website.
To listen to this presentation live on the Internet, visit https://investors.thecignagroup.com/events-and-presentations/default.aspx at least 15 minutes prior to the presentation to download and install any necessary audio software.
About The Cigna Group
The Cigna Group (NYSE: CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Evernorth Health Services, Cigna Healthcare, or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 countries and jurisdictions, and has approximately 165 million customer relationships around the world. Learn more at thecignagroup.com.
Investor Relations Contact
Ralph Giacobbe
1 (860) 787-7968
Ralph.Giacobbe@ThecignaGroup.com
Media Contact
Justine Sessions
1 (860) 810-6523
Justine.Sessions@Evernorth.com
| Last Trade: | US$304.14 |
| Daily Change: | -11.60 -3.67 |
| Daily Volume: | 1,480,627 |
| Market Cap: | US$84.600B |
January 30, 2025 October 31, 2024 September 12, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
